Nippon Life Global Investors Americas Inc. acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 88,800 shares of the medical equipment provider’s stock, valued at approximately $3,796,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Parnassus Investments CA grew its holdings in shares of Hologic by 88.6% during the fourth quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock worth $608,797,000 after buying an additional 6,689,454 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Hologic by 5.8% in the 4th quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock valued at $265,008,000 after purchasing an additional 342,239 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Hologic by 5.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock valued at $72,243,000 after purchasing an additional 105,360 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Hologic by 3.5% during the 3rd quarter. Legal & General Group Plc now owns 1,426,469 shares of the medical equipment provider’s stock valued at $52,333,000 after acquiring an additional 48,577 shares during the period. Finally, TD Asset Management Inc. lifted its position in shares of Hologic by 4.8% during the 3rd quarter. TD Asset Management Inc. now owns 1,309,247 shares of the medical equipment provider’s stock valued at $48,036,000 after acquiring an additional 59,865 shares during the period. Institutional investors and hedge funds own 97.59% of the company’s stock.
Hologic, Inc. (HOLX) traded down $0.34 during trading on Wednesday, hitting $38.44. 1,450,000 shares of the stock traded hands, compared to its average volume of 2,670,000. The company has a market capitalization of $10,630.00, a PE ratio of 14.67, a PEG ratio of 1.76 and a beta of 0.84. Hologic, Inc. has a twelve month low of $35.33 and a twelve month high of $46.80. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The firm had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. During the same period last year, the firm posted $0.52 earnings per share. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. equities research analysts forecast that Hologic, Inc. will post 2.25 earnings per share for the current year.
In other news, Director Namal Nawana bought 6,600 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the purchase, the director now owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.88% of the stock is currently owned by company insiders.
Several research analysts recently issued reports on the company. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Canaccord Genuity reiterated a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Friday, February 9th. Royal Bank of Canada reissued a “hold” rating and set a $44.00 price objective on shares of Hologic in a research note on Friday, February 9th. Needham & Company LLC reissued a “buy” rating and set a $50.00 price objective on shares of Hologic in a research note on Friday, February 9th. Finally, Stifel Nicolaus cut shares of Hologic from a “buy” rating to a “hold” rating and decreased their price target for the stock from $45.00 to $42.00 in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $48.00.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.